Table 2 Intraoperative and histopathological outcomes and postoperative adjuvant therapy
Laparoscopic approach (n = 136) | Open approach (n = 65) | p value | |
|---|---|---|---|
Operative time, hours, mean ± SD | 3.7 ± 1.3 | 3.3 ± 1.0 | 0.005 |
Estimated blood loss, ml, mean ± SD | 190.90 ± 133.43 | 247.87 ± 201.71 | 0.031 |
Lymph node count, median (Range) | 30 (19.5, 37) | 29 (14.5, 38) | 0.959 |
Lymph node metastases, n (%) | 8 (5.9%) | 2 (3.1%) | 0.505 |
Stage, n (%) | 0.372 | ||
I | 119 (87.5%) | 61 (93.8%) | |
II | 12 (8.8%) | 2 (3.1%) | |
III | 5 (3.7%) | 2 (3.1%) | |
Grade, n (%) | 0.791 | ||
G1 | 69 (50.7%) | 31 (47.7%) | |
G2 | 43 (31.6%) | 24 (36.9%) | |
G3 | 24 (17.6%) | 10 (15.4%) | |
Postoperative histology, n (%) | 0.816 | ||
Endometrioid adenocarcinoma FIGO grade I-II | 77 (56.6%) | 38 (58.5%) | |
Endometrioid adenocarcinoma FIGO grade III | 48 (35.3%) | 24 (36.9%) | |
Serous adenocarcinoma | 5 (3.7%) | 1 (1.5%) | |
Clear cell adenocarcinoma | 3 (2.2%) | 2 (3.1%) | |
Carcinosarcoma | 3 (2.2%) | 0 (0.0%) |